Epigenetics Market Research, 2030
The global epigenetics market was valued at $1.0 billion in 2020, and is projected to reach $4.1 billion by 2030, growing at a CAGR of 14.8% from 2021 to 2030. Epigenetics is a branch of genetics that studies cellular and physiological characteristic variations caused by environmental or environmental factors that switch genes on and off and impact cellular capacity to read genes without being influenced by changes in genotype. Epigenetics causes changes in an organism's phenotype rather than genotype, although the underlying DNA or RNA sequence remains unchanged. Epigenetic changes are important for development because they are dynamic and change in response to environmental stimuli.
The growth of the epigenetics market is majorly driven due to technological advancements associated with epigenetics. Epigenetics-based assays are highly useful and advantageous as compared to traditional microarrays, owing to advantages such as need for low concentration of input sample and lack of experimental bias in microarrays. Researchers have focused on developing advanced epigenetic instruments and sequencing platforms.
In addition, increase in incidences of cancer, infectious diseases, and genetic conditions also drives the market. Drugs derived through thorough epigenetic research efficiently work on a specific type of cancer, which enables it to reduce treatment costs and deliver treatment at reasonable prices in developing and undeveloped countries. When compared to traditional cancer treatments, epigenetics provides focused therapeutic actions that target only diseased and malignant cells in the host. Thus, increase in global incidences of cancer is expected to significantly drive growth of the epigenetics industry.
Moreover, R&D activities related to DNA sequencing have gained traction, owing to high investments in DNA sequencing technologies and extensive work on genome projects across the globe. Research in the field of healthcare is on the rise, owing to growth in patient base worldwide. Moreover, the need for better quality healthcare also generates a need for research in the field of healthcare. Therefore, governments of different nations plan to focus on investments in healthcare research to suffice quality standards and meet needs of patients for newer and better technologies. Thus, increase in number of research projects significantly supports the epigenetics market growth.
However, standardization concerns over epigenetics based diagnostics and dearth of skilled professionals is expected to impede the growth of the market. Conversely, increasing application of epigenetics for non-oncology applications and increasing patient pool for personalized medicine offers lucrative opportunities for the market; hence, is a great epigenetics market opportunity for the key players to invest.
In addition, the COVID-19 outbreak is anticipated to have a positive impact on the epigenetics market. A huge number of clinics and hospitals across the globe were restructured to increase the hospital capacity for patients diagnosed with COVID-19. Non-essential procedures took a potential backlog due to rapid rise in COVID-19 cases. Researchers have begun to understand how epigenetics may prevent viral proliferation so that vaccines and therapeutics can be developed to specifically target replicating mechanisms of a virus. Thus, rise in number of epigenetic researches and growth in awareness of epigenetic drugs for treatment of coronavirus infection is anticipated to have an overall positive impact on the epigenetics industry.
Epigenetics Market Segmentation
The epigenetics market is segmented on the basis of product, application, end user, and region. By product, it is divided into enzymes, kits, instruments, and reagents. The enzymes segment is further divided into DNA ligases, DNA polymerases, other DNA-modifying enzymes, acetylases, methyltransferases, other protein-modifying enzymes, reverse transcriptase, RNA ligases, and other RNA-modifying enzymes. The kits segment epigenetics market share is further subdivided into ChIP sequencing kits, bisulfite conversion kits, whole genome amplification kits, 5-hmC & 5-mC analysis kits, and RNA sequencing kits, and others. The instrument segment is further categorized into mass spectrometers, next-generation sequencers, qPCRs, sonicators, and others. The reagents segment is further divided into antibodies, buffers, histones, magnetic beads, primers, and others.
On the basis of application, the market is segmented into oncology and non-oncology. The oncology segment is further sub segmented into solid tumors and liquid tumors. Non-oncology applications include metabolic diseases, infectious diseases, inflammatory diseases, cardiovascular diseases, and other applications. By end user, it is segmented into academic & government research institutes, pharmaceutical & biotechnology companies, and contract research organizations (CROs).
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Latin America and Middle East & Africa).
Based on type, the kits segment held the largest epigenetics market share in the global market in 2020 and is expected to remain dominant during the forecast period, owing to rise in availability and growth in adoption of epigenetic kits due to is high sensitivity and rapid results.
On the basis of application, the oncology segment held the largest epigenetics market share in 2020 and is expected to remain dominant during the forecast period, owing to significant rise in the cases of cancer.
On the basis of end user, the pharmaceutical & biotechnology companies segment held the largest epigenetics market size in 2020 and is expected to remain dominant during the forecast period, due to R & D for drug resistance developed by microorganisms, oncology, molecular aspects of cancer, and drug discovery for non-oncology applications.
North America exhibited the highest epigenetics market size in the global epigenetics market in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to developed healthcare infrastructure, wide availability of advanced epigenetics products, large presence of key players, and presence of trained medical professionals. However, Asia-Pacific is expected to witness highest growth rate during the forecast period, attributable to rise in awareness related to epigenetics, increase in penetration of key players in emerging countries in Asia-Pacific, and development in infrastructure for research and clinical settings. Moreover, China and India are expected to witness growth at high CAGR in the Asia-Pacific epigenetics market forecast.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epigenetics market analysis from 2020 to 2030 to identify the prevailing epigenetics market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the epigenetics market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global epigenetics market trends, key players, market segments, application areas, and market growth strategies.
Epigenetics Market Report Highlights
By End User
Key Market Players
Active Motif, Inc., QIAGEN N.V., Abcam Plc., Merck Millipore, Hologic Inc., Thermo Fisher Scientific Inc., Illumina Inc., PerkinElmer, Inc., Zymo Research, Agilent Technologies, Inc.
This section provides opinions of top-level CXOs in the epigenetics industry. According to CXOs, epigenetics has enhanced diverse fields of life sciences by research, innovation, and development. Oncology-and non-oncology-related investigation areas, such as developmental biology & drug discovery, are anticipated to benefit through epigenetic interventions.
CXOs further stated that the epigenetics market has gained momentum, owing to surge in number of genome mapping projects across the globe, significant technological advancements in epigenetics, and surge in prevalence of cancer and other chronic diseases. In addition, rise in awareness regarding epigenetics and its advantages supplement the market growth. Emerging economies in Asia-Pacific and LAMEA are expected to present lucrative growth opportunities to key players in the industry.
According to perspectives of CXOs of leading companies in the market, demand for DNA sequencing has significantly increased, owing to increase in research, innovation, and development sectors. In addition, owing to increase in cancer prevalence globally, significant technological advancements in epigenetics research and surge in collaborations & partnerships among academic & government research institutes and pharmaceutical & biotechnology companies globally majorly influence the market growth.
Utilization of epigenetics products is higher in pharmaceutical & biotechnology companies and in academic & government research institutes, owing to epigenetic studies, such as acetylation, histone modification, DNA methylation, and other studies that facilitate in their research. Employment of technologically advanced epigenetics products is highest in North America, owing to increase in adoption of epigenetics products, followed by Europe and Asia-Pacific.